FDA Vaccine Chief Dr. Vinay Prasad to Depart in April
Dr. Vinay Prasad, the director of the Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research, will abandon the agency at the end of April. His departure follows a period of increasing criticism of the FDA’s drug and vaccine approval processes.
A Second Departure for a Controversial Figure
This marks Dr. Prasad’s second departure from the position. He briefly stepped down in July following backlash over his regulatory decisions, but returned two weeks later in August. He will return to the University of California, San Francisco, where he previously taught according to the New York Times.
Mounting Criticism of the FDA
Dr. Prasad’s decision comes amid mounting criticism of the FDA from the biotech and pharmaceutical industries, as well as from former health officials. In the past year, the agency has denied or discouraged the approval applications of at least eight drugs, citing concerns with the data provided by the companies as reported by CNBC.
Regulatory Uncertainty and Reversals
Companies have accused the FDA of reversing previous guidance on the evidence required for approval, creating regulatory uncertainty that could stifle the development of treatments for difficult-to-treat diseases. The FDA initially refused to review Moderna’s flu shot, but later reversed course, adding to these concerns.
Recent Controversies
The most recent controversy involved the FDA discouraging UniQure from applying for expedited approval of its experimental treatment for Huntington’s disease. The agency requested a new study to support the approval, a request that UniQure and patient advocates argued was overly burdensome as noted by USA Today.
FDA Response and Staffing Changes
The FDA maintains that its decisions are based on evidence and that it is conducting rigorous, independent reviews. Though, the agency has also faced broader backlash and undergone staff cuts and an overhaul under Health and Human Services Secretary Robert F. Kennedy Jr. The Hill reports.
Makary’s Statement and Successor Search
FDA Commissioner Dr. Marty Makary stated that Dr. Prasad “got a tremendous amount accomplished” during his tenure and that the FDA will appoint a successor before his departure. CNBC also reported that Makary appeared to criticize UniQure’s gene therapy for Huntington’s disease in a recent interview.